(Q38034134)

27 August 2017

title

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings (English)

1 reference

27 August 2017

3

Crystal Watson

1 reference

27 August 2017

Machaon Bonafede

1

1 reference

27 August 2017

Kathleen M Fox

series ordinal

2

1 reference

27 August 2017

Nicole Princic

series ordinal

4

1 reference

27 August 2017

Shravanthi R Gandra

series ordinal

5

1 reference

27 August 2017

language of work or name

English

0 references

publication date

8 August 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

29

1 reference

27 August 2017

issue

8

1 reference

27 August 2017

page(s)

664-674

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-012-0037-5

27 August 2017

exact match

0 references

cites work

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0037-5

10.1007/S12325-012-0037-5

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1021175113

0 references

1 reference